Prevalence of Radiological Signs of Dysthyroid Optic Neuropathy in Magnetic Resonance Imaging in Patients with Active, Moderate-to-Severe, and Very Severe Graves Orbitopathy
Sign Up to like & getrecommendations! Published in 2018 at "European Thyroid Journal"
DOI: 10.1159/000486828
Abstract: Background: Differentiating between dysthyroid optic neuropathy (DON), which requires urgent therapy to prevent blindness, and moderate-to-severe Graves orbitopathy (GO) remains challenging. There is no pathognomonic feature of DON in either ophthalmological or radiological examinations. Objectives:… read more here.
Keywords: graves orbitopathy; active moderate; dysthyroid optic; optic neuropathy ... See more keywords
Role of teprotumumab in the treatment of active moderate-to-severe Graves' orbitopathy.
Sign Up to like & getrecommendations! Published in 2022 at "European thyroid journal"
DOI: 10.1530/etj-22-0185
Abstract: Graves' orbitopathy (GO), also named thyroid-associated orbitopathy (TAO) or thyroid-eye disease (TED), is an autoimmune inflammatory disease of the orbit and the most important extrathyroidal manifestation of Graves' disease. After an initial inflammatory ("active") phase… read more here.
Keywords: role teprotumumab; graves orbitopathy; treatment active; active moderate ... See more keywords
Therapy With Different Dose Regimens of Rituximab in Patients With Active Moderate-To-Severe Graves’ Orbitopathy
Sign Up to like & getrecommendations! Published in 2022 at "Frontiers in Endocrinology"
DOI: 10.3389/fendo.2021.790246
Abstract: Background Immunosuppressive therapy of Graves’ orbitopathy (GO) is indicated during the active phase of disease. Intravenous steroids (IVGC) are effective in about 70% of patients, although unresponsiveness or relapse are observed. In previous studies, rituximab… read more here.
Keywords: disease; graves orbitopathy; therapy; active moderate ... See more keywords